Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[996]

I think the flu will bring them extra revenues, they hinted on that in one of their last news-items.

"We strengthened our product line, by launching Radix Isatidis Dispersible Tablets to treat viral influenza and by adding 22 TCM products to our portfolio from our acquisition of Hongrui. We are focused on continuing to expand our portfolio of high margin drugs that address major disease categories and on continuing to build sustainable growth in revenues and profits."

(At least that is what I read between the lines.)